GlaxoSmithKline and Regeneron have given their backing to a new project that will use patient data held by the UK Biobank.
The firms will get free access to the samples in return for covering the cost of sequencing it and, after a period of exclusivity, they will then allow the data to be plugged back into the resource for wider use.
Eli Lilly and Company has publicized plans to invest $850 million in the United States throughout 2017.
The media release, delivered Friday, follows a meeting between Lilly executives, federal, state and local government officials at Lilly Technology Center in Indianapolis, Indiana.
Once again, more than three-quarters of U.S. venture capital (VC) dollars went to companies in California, New York and Massachusetts in 2016, according to data from the PricewaterhouseCoopers (PwC)/CB Insights’ Moneytree Report Explorer. Approximately 53.3 percent of all VC capital went to California companies, down nearly 4.4 percent from the states peak in 2014 (57.7) and down 3.9 percent from 2016. While California’s share declined, both Massachusetts and New York saw increases in their share of VC dollars invested:
Patients everywhere take their medication with emocha.
This World TB Day, we want to say thank you to our partners around the world who are uniting to #EndTB.
Patients across three continents are using the emocha platform to facilitate TB treatment, and we’re proud to support hundreds of healthcare workers as they fight to eradicate TB.
Public health departments in California, Maryland, Texas, Missouri, Washington, Rhode Island, and Puerto Rico have adopted emocha’s video DOT platform for active and latent TB monitoring. Sites in Australia, India, and Mexico have also implemented the technology, proving that video DOT is an effective strategy for combating global TB.
Patients could one day self-administer vaccines using a needleless, pill-sized technology that jet-releases a stream of vaccine inside the mouth, according to a proof-of-concept study conducted at UC Berkeley.
The study did not test vaccine delivery in people, but demonstrated that the technology, called MucoJet, is capable of delivering vaccine-sized molecules to immune cells in the mouths of animals. The technology is a step toward improved oral vaccine delivery, which holds the promise of building immunity in the mouth’s buccal region of cells, where many infections enter the body. When patients hold the MucoJet against the inside of their cheek, the device releases a jet stream that directly targets the buccal region. This region is rich in immune cells but underutilized in immunology because of the challenge of efficiently penetrating the thick mucosal layer in this part of the oral cavity with existing technologies, such as the oral spray often used for influenza vaccination.
Get a sneak peak of the Mobile eXploration Lab (MXLab) – the country’s largest, most advanced mobile STEM laboratory! MdBio is launching the MXLab for the 2017/2018 school year, and we want to give teachers across the state the first chance to see the lab in action and provide feedback on our activities for Maryland high schools.
Join us at one of five events across the state to get a sneak peek of the MXLab plus a hands-on teacher professional development activity for your classroom.
On Tuesday, March 7, 2017, the University of Maryland (UMD) Robert E. Fischell Institute for Biomedical Devices and RTI International (link is external) welcomed nearly 150 representatives of Maryland’s medical device ecosystem to a daylong event focused on bringing products from invention to market in the state. The event, Medical Device Innovation in Maryland: from Technology to Lab to Market, took place at the UMD campus in College Park, and culminated with a tour of the soon-to-be new home of the A. James Clark School of Engineering: A. James Clark Hall.
“This is the start of an incredibly exciting time for biomedical devices in Maryland – and you’re here at the beginning,” University of Maryland Provost Mary Ann Rankin told attendees.
Symbiomix today announced that the US Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for its lead investigational product candidate Solosec™ (secnidazole oral granules), an innovative antibiotic designed to treat bacterial vaginosis (BV). In accordance with the FDA’s priority 6-month review designation, the agency has established a user-fee goal date under the Prescription Drug User Fee Act (PDUFA) of September 17, 2017. Symbiomix submitted the NDA filing in January 2017.
Solosec™ is a potent, next-generation, investigational 5-nitroimidazole antibiotic with enhanced pharmacokinetic properties, which will be the first and only single-dose oral therapy approved for BV if approved by the FDA. The FDA previously designated Solosec™ as a Qualified Infectious Disease Product (QIDP) for the treatment of BV and granted it Fast Track designation, which made Solosec™ eligible for priority review and at least 10 years of market exclusivity.
What’s next for the pharmaceuticals industry, amid digital disruption and rapid technological advances? McKinsey’s Martin Dewhurst sat down for a wide-ranging conversation with David Epstein of venture firm Flagship Pioneering to explore ways the sector could shift in coming years. In this interview, part of our Biopharma Frontiers series on how the pharmaceutical industry is evolving and how leaders can adapt, Epstein discusses the next horizon of innovation, critical elements of an effective business, and the kind of culture he tries to foster. An edited transcript of their conversation follows.
Dear Friends of CONNECTpreneur:
I hope everything is well! This is a “Last Call” for our April 4 Big Idea CONNECTprenuer SPRING FORUM at the Hyatt Regency in Bethesda, MD. We expect over 500 CXOs, founders, entrepreneurs, angel investors, etc., and we will be completely SOLD OUT again. So, please sign up now!
We have unparralled CXO to CXO networking, plus an amazing program:
Fireside chat with DAVID TRONE, Co-Founder and Owner, Total Wine & More
Awesome Entrepreneur “War Stories” Panel (moderated by GLEN HELLMAN (aka Mr. Cranky), angel investor and CEO of Driven Forward) featuring:
· NIGEL JONES, CEO of Koolspan and Managing Director of TWJ Capital
· BETH MALONEY, President of Palladian Partners
· D.P. VENKATESH, VP of Broadsoft and CEO of mPortal
PLUS 9 awesome early stage companies will present their companies.
